This is quite a boring product but access to the US market is a very big deal. It's true this is the best option available for v/q scanning and so very likely that most, if not all, nuclear medicine departments in the US will be using this in time. Whether they can land their "beyond PE" strategy is an open question. There are specific use cases (for example the use of endobronchial valves in COPD and possibly if there is a push for early Rx of very mild COPD with Ensifentrine or similar). Once established, the ongoing consumables and supply should mean this is a very reliable revenue stream going forward. All IMO, DYOR.
CYC Price at posting:
$2.95 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)